Clinical Trial Update: JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial of JS111 is recruiting for patients with advanced non-small cell lung cancer harboring EGFR mutations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• JS111

Snippet

Sponsor: Suzhou Junjing BioSciences Co., Ltd. | Conditions: NSCLC | Phase 1, Phase 2 | Status: RECRUITING